WO2005072752A1 - 高リン血症の予防又は治療剤 - Google Patents
高リン血症の予防又は治療剤 Download PDFInfo
- Publication number
- WO2005072752A1 WO2005072752A1 PCT/JP2005/001052 JP2005001052W WO2005072752A1 WO 2005072752 A1 WO2005072752 A1 WO 2005072752A1 JP 2005001052 W JP2005001052 W JP 2005001052W WO 2005072752 A1 WO2005072752 A1 WO 2005072752A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- integer
- hyperphosphatemia
- formula
- compound
- Prior art date
Links
- 201000005991 hyperphosphatemia Diseases 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 title claims abstract description 23
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 16
- 230000003449 preventive effect Effects 0.000 title claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 57
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 10
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 9
- 125000003118 aryl group Chemical group 0.000 claims abstract description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 229920000642 polymer Polymers 0.000 claims description 8
- 229920001400 block copolymer Polymers 0.000 claims description 6
- 229920003169 water-soluble polymer Polymers 0.000 claims description 6
- 238000005349 anion exchange Methods 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 206010010774 Constipation Diseases 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 238000009825 accumulation Methods 0.000 abstract description 4
- 229910052782 aluminium Inorganic materials 0.000 abstract description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract description 4
- 239000011575 calcium Chemical class 0.000 abstract description 4
- 229910052791 calcium Inorganic materials 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 206010022694 intestinal perforation Diseases 0.000 abstract description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract description 3
- 239000011777 magnesium Chemical class 0.000 abstract description 3
- 229910052749 magnesium Inorganic materials 0.000 abstract description 3
- 208000008384 ileus Diseases 0.000 abstract description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 33
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- 229910052757 nitrogen Inorganic materials 0.000 description 23
- -1 3,4-methylenedioxyphenyl group Chemical group 0.000 description 22
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 22
- 229910019142 PO4 Inorganic materials 0.000 description 19
- 239000010452 phosphate Substances 0.000 description 19
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 12
- 229910052698 phosphorus Inorganic materials 0.000 description 12
- 239000011574 phosphorus Substances 0.000 description 12
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000005259 measurement Methods 0.000 description 10
- 229920001223 polyethylene glycol Polymers 0.000 description 10
- 239000000203 mixture Substances 0.000 description 8
- 238000006116 polymerization reaction Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- AHLWZBVXSWOPPL-RGYGYFBISA-N 20-deoxy-20-oxophorbol 12-myristate 13-acetate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(C=O)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C AHLWZBVXSWOPPL-RGYGYFBISA-N 0.000 description 7
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 241001602688 Pama Species 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- IJJSYKQZFFGIEE-UHFFFAOYSA-N naphthalene;potassium Chemical compound [K].C1=CC=CC2=CC=CC=C21 IJJSYKQZFFGIEE-UHFFFAOYSA-N 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 239000003463 adsorbent Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000003999 initiator Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KHNXRSIBRKBJDI-UHFFFAOYSA-N Sevelamer hydrochloride Chemical compound Cl.NCC=C.ClCC1CO1 KHNXRSIBRKBJDI-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003957 anion exchange resin Substances 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 208000003243 intestinal obstruction Diseases 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 229960003027 sevelamer hydrochloride Drugs 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102000006335 Phosphate-Binding Proteins Human genes 0.000 description 2
- 108010058514 Phosphate-Binding Proteins Proteins 0.000 description 2
- 238000000944 Soxhlet extraction Methods 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000007805 chemical reaction reactant Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 125000003163 2-(2-naphthyl)ethyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(C([H])=C([H])C2=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- SJIXRGNQPBQWMK-UHFFFAOYSA-N 2-(diethylamino)ethyl 2-methylprop-2-enoate Chemical compound CCN(CC)CCOC(=O)C(C)=C SJIXRGNQPBQWMK-UHFFFAOYSA-N 0.000 description 1
- ADSOSINJPNKUJK-UHFFFAOYSA-N 2-butylpyridine Chemical compound CCCCC1=CC=CC=N1 ADSOSINJPNKUJK-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- VAEVAPKMDALDOK-UHFFFAOYSA-N 2-methylprop-2-enoic acid;phthalic acid Chemical compound CC(=C)C(O)=O.OC(=O)C1=CC=CC=C1C(O)=O VAEVAPKMDALDOK-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- NFOQRIXSEYVCJP-UHFFFAOYSA-N 2-propoxycarbonylbenzoic acid Chemical compound CCCOC(=O)C1=CC=CC=C1C(O)=O NFOQRIXSEYVCJP-UHFFFAOYSA-N 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010020669 Hypermagnesaemia Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000953555 Theama Species 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 208000020560 abdominal swelling Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001346 alkyl aryl ethers Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000004645 aluminates Chemical class 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229940107170 cholestyramine resin Drugs 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000001465 metallisation Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- REOJLIXKJWXUGB-UHFFFAOYSA-N mofebutazone Chemical group O=C1C(CCCC)C(=O)NN1C1=CC=CC=C1 REOJLIXKJWXUGB-UHFFFAOYSA-N 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000005542 phthalazyl group Chemical group 0.000 description 1
- 229920000083 poly(allylamine) Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- NHARPDSAXCBDDR-UHFFFAOYSA-N propyl 2-methylprop-2-enoate Chemical compound CCCOC(=O)C(C)=C NHARPDSAXCBDDR-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
Definitions
- the present invention relates to a prophylactic or therapeutic agent for hyperphosphatemia, and more particularly to a preventive or therapeutic agent for hyperphosphatemia which contains a high-potency, water-soluble polymer having phosphate binding ability as an active ingredient. Regarding therapeutic agents.
- Non-Patent Document 1 In maintaining homeostasis of serum phosphorus concentration, excretion of phosphorus in urine is the most important factor, and hyperphosphatemia often appears when renal function is impaired. As a result, secondary hyperparathyroidism is induced (see Non-Patent Document 1), and particularly in dialysis patients, the risk of death due to cardiovascular disease associated with ectopic calcification, particularly coronary calcification, is increased. It has been pointed out that this may be the cause (see Non-Patent Document 2). Therefore, suppression of hyperphosphatemia is extremely important for patients with renal failure.
- Patent Document 1 W ⁇ 95 / 05184
- Patent Document 2 Japanese Patent Application Laid-Open No. 9-295941
- Non-patent document 1 Kakagami et al. Clinical Calcium, 11 (10), 1267, 2001
- Non-Patent Document 2 Shioi et al. Pharmaceutical Journal, 39 (5), 1493, 2003
- Non-Patent Document 3 Masao Kim Dialysis Care Vol.6 No6: 20-21, 2000
- Non-patent document 4 Yoshinori Tsuruta, "Polymer synthesis reaction new revision", Nikkan Kogyo Shimbun, 1986
- Non-patent document 5 M. Vamvakaki et al. Macromolecules 1999, 32, 2088
- the present invention provides a method for preventing or preventing hyperphosphatemia which is easy to take without causing diseases caused by absorption or accumulation of inorganic salts such as aluminum, calcium and magnesium, or side effects such as constipation, intestinal perforation and intestinal obstruction. It is intended to provide a therapeutic agent.
- the present inventors have conducted intensive studies in order to solve the above-mentioned problems, and as a result, have found that a certain type of polymer having anion-exchange ability has S-phosphate binding ability and is water-soluble. Does not cause the absorption or accumulation of inorganic salts, and The present inventors have found that there are no side effects such as constipation, intestinal perforation, and intestinal obstruction, which are problems with the resin replacement preparation, and that they are easy to take even for elderly people, and have completed the present invention.
- one aspect of the present invention is a preventive or therapeutic agent for hyperphosphatemia comprising a block copolymer of a polymer having an anion exchange ability and a water-soluble polymer as an active ingredient.
- the preventive or therapeutic agent for hyperphosphatemia of the present invention is a water-soluble polymer having a phosphate binding ability.
- a water-soluble polymer having a phosphate binding ability By binding to phosphate in the gastrointestinal tract by oral administration and excreting it in feces, it is possible to suppress the intake of phosphate from food and reduce the phosphate concentration in serum.
- it since it is water-soluble, it can be provided as a drug that is less likely to cause constipation, abdominal distension, intestinal perforation, intestinal obstruction, and the like, and that can be easily taken by elderly people with reduced swallowing ability.
- FIG. 1 shows a 1 H-NMR chart of a test compound (A_l).
- FIG. 2 shows a 1 H-NMR chart of test compound (B).
- FIG. 3 shows a 1 H-NMR chart of test compound (C).
- FIG. 4 is a graph showing the in vitro phosphoric acid adsorption ability of a test compound (A-17).
- FIG. 5 is a graph showing the in vivo serum phosphate adsorbing ability of the test compound (A-7) (each group: expressed as mean soil standard error).
- FIG. 6 is a graph showing the area under the serum phosphate curve ( ⁇ AUC (0-180 min), (mg ⁇ min / dL)) and the statistical analysis results of the test compound (A-7) in vivo. (Each group: expressed as mean soil standard error). #: There is a significant difference compared to the disease control group at p ⁇ 0.01 (t-test). *: At p ⁇ 0.05, there is a significant difference compared to the disease control group (Dunnett multiple comparison test).
- Another embodiment of the present invention provides a compound represented by the following formula (I): [0016] [Formula 1]
- R 1 and R 2 are the same or different and represent an alkyl group, an aryl group or an aryl group, R 3 represents a hydrogen atom or a methyl group, R 4 represents a C alkoxy group, and k represents 1
- 1-5 represents an integer of 6
- m and n are integers of 1 or more
- m / n represents 0.5-5.
- n represents an integer of 20 to 200. It is a preventive or therapeutic agent for hyperphosphatemia contained as a component.
- R 1 and R 2 are the same or different and each of C 1
- R 4 represents an alkoxy group of C
- k represents an integer of 2 or 3
- m represents 5
- N is an integer of 0 to 300
- n is an agent for preventing or treating hyperphosphatemia containing the compound or a pharmaceutically acceptable salt thereof, which represents an integer of 20 to 200, as an active ingredient.
- R 1 and R 2 are the same or different and each of C 1
- R 1-5 represents an alkyl group
- R 3 represents a methyl group
- R 4 represents a C alkoxy group
- k represents 2 or
- n represents an integer of 20-200.
- R 1 and R 2 are the same or different and each of C 1
- R 1-5 represents an alkyl group
- R 3 represents a methyl group
- R 4 represents a methoxy group
- k represents 2
- m represents an integer of 50-300
- n represents an integer of 20-200. It is a prophylactic or therapeutic agent for hyperphosphatemia containing a compound or a pharmaceutically acceptable salt thereof as an active ingredient.
- the polymer having an anion exchange ability of the present invention is a polymer composed of a monomer having an amino group, an ammonium group, a pyridine group, a pyrimidium group, an imidazole group, an imidazolium group, or the like,
- water-soluble polymer of the present invention examples include polyethylene glycol, monoalkoxypolyethylene glycol, polypropylene glycol, and monoalkoxypolypropylene glycol.
- the preventive or therapeutic agent for hyperphosphatemia of the present invention is prepared by block copolymerizing a polymer having anion exchange ability and a water-soluble polymer.
- alkyl group in the definition of R 1 and R 2 refers to a straight-chain or branched-chain alkyl group, for example, a methynole group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, t Monobutyl group, pentyl group, isopentyl group, 1-ethylpropyl group and the like.
- the “aryl group” in the definition of R 1 and R 2 represents a substituted or unsubstituted aryl group.
- Such aryl groups include, for example, phenyl, 1_naphthyl, 2_naphthyl Group, 3,4-methylenedioxyphenyl group, 3- (methylsulfonyl) phenyl group, 2-triphenolylmethylphenyl group, 3-cyanophenyl group, 2-fluorophenyl group, 2-ethoxynaphthyl group, 2-dimethylaminophenyl, 3-butylsulfonylaminonaphthyl, 2-carboxyphenyl, 3,4-dimethoxyphenyl, 4-[(N, N-dimethylaminomethylene) aminosulfonyl ] Phenyl, benzyl, phenethyl, 3-phenylpropyl, 1_naphthylmethyl, 2_ (1_nap
- the heteroaryl group refers to a substituted or unsubstituted heteroaryl group.
- Such heteroaryl groups include, for example, pyrrolyl, furyl, chenyl, oxazolyl, isoxazolyl, imidazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, tetrazolyl, 1,3,5- 1,2,4-thiadiazolyl group, 1,2,4-thiadiazolyl group, pyridinole group, pyrazul group, pyrimidinyl group, pyridazinyl group, 1,2,4-tritodininole group, 1,2,3— Tri-tininole group, 1,3,5-tri-ininole group, benzixoxazolyl group, benzisoxazolyl group, benzothiazolyl group, benzoisothiazolyl group, benzimidazolyl group, thianaphthul group,
- R 1 and R 2 are an alkyl group having 115 carbon atoms, more preferred examples are an alkyl group having 13 carbon atoms, and particularly preferred examples are a methyl group and an ethyl group. is there. [0027] R represents a hydrogen atom or a methyl group, and is preferably a methyl group.
- R 4 is an alkoxy group having 11 to 15 carbon atoms, a more preferred example is an alkoxy group having 13 to 13 carbon atoms, and a particularly preferred example is a methoxy group.
- k is an integer of 1 to 6, preferably 2 or 3, and more preferably 2.
- m and n are integers of 1 or more, preferably, m is 50-300, and n is 20,200. More preferably, m is 90-150 and n is 25-50.
- m / n is 0.5-5.
- the degree of polymerization (m and n) of the compound of formula (I) of the present invention can be controlled by the molar ratio of the initiator, the molar ratio of the monomer, and the reaction temperature (see Non-Patent Document 4).
- the "pharmaceutically acceptable salts" in the present invention include, for example, salts with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, butyric acid, lactic acid, malic acid, Salts with organic acids such as citric acid, tartaric acid, fumaric acid, maleic acid, benzenesulfonic acid, and methanesulfonic acid, and salts with acidic amino acids such as aspartic acid and gnoretamic acid.
- inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, butyric acid, lactic acid, malic acid
- Salts with organic acids such as citric acid, tartaric acid, fumaric acid, maleic acid, benzenesulfonic acid, and methanesulfonic acid
- salts with acidic amino acids such as aspartic acid and
- the compound of formula (I) of the present invention can be produced by the following reaction formula.
- an inert gas eg, By reacting an equimolar amount of a metalating agent (for example, naphthalene potassium) with a compound of formula ( ⁇ ) (wherein R 4 is as defined above, for example, 2-methoxyethanol) under an air stream, III) A compound (in the formula, R 4 is as defined above, and M represents a monovalent metal atom) is obtained.
- a metalating agent for example, naphthalene potassium
- Ethylene oxide is added to the compound of formula ( ⁇ ) as a reaction initiator, polymerization is carried out at room temperature (preferably 25 ° C.), and a compound of formula (IV) (where m is 1 or more, Is an integer.).
- reaction solution is dropped into a cooled poor solvent (eg, isopropyl alcohol) to precipitate a target compound, and the precipitate is dissolved in a suitable good solvent (eg, tetrahydrofuran),
- a suitable good solvent eg, tetrahydrofuran
- the desired compound of formula (I) (m and n are integers of 1 or more) can be obtained by lyophilization and recovery.
- the agent for preventing and treating hyperphosphatemia of the present invention can be formulated into a solution, a jelly or the like by utilizing the property of dissolving the compound of formula (I) in water.
- the compound of formula (I) can be formulated as a solid by mixing it with a solid preparation which is dissolved at the time of use, or a general solid preparation such as a tablet or powder. No particular method is required for formulation, and each formulation can be prepared by a conventional method.
- the preventive and therapeutic agent for hyperphosphatemia of the present invention can be orally administered to adults in an amount of 0.120 g once or several times a day.
- the dose can be adjusted according to age, weight, symptoms, etc., as appropriate.
- Carriers used for the preparation of preparations in oral liquid preparations include surfactants such as sucrose fatty acid esters, polyoxyl stearate, polyoxyethylene polyoxypropylene glycols, polyoxyethylene mono fatty acid esters, and the like.
- surfactants such as sucrose fatty acid esters, polyoxyl stearate, polyoxyethylene polyoxypropylene glycols, polyoxyethylene mono fatty acid esters, and the like.
- H adjuster There is an H adjuster, and if necessary, a solubilizer, a buffer, a preservative, a flavor, a pigment, a sweetener and the like can be used.
- Carriers used in the preparation of solid preparations include excipients such as lactose, starch, sugar, mannitol and crystalline cellulose, and binders such as hydroxypropylcellulose, hydroxypropylmethylcellulose, gelatin and PVP.
- Disintegrators such as carboxymethylcellulose calcium and low-substituted hydroxypropylcellulose, and lubricants such as magnesium stearate, hydrogenated castor oil, and talc.
- dissolution aids, buffers, and preservatives as necessary Fragrances, pigments, flavoring agents and the like can be used.
- the agent for preventing or treating hyperphosphatemia of the present invention may optionally contain other active ingredients in addition to the above components as long as the effects of the present invention are not impaired.
- a small amount of a sample for GPC measurement was drawn from the reaction solution with a syringe, 4.3 mL of dimethylaminoethyl 2-methacrylate (AMA) was added, the reaction was allowed to proceed under water cooling for 20 minutes, and the reaction was stopped using a small amount of methanol. did. After concentrating the reaction solution, distilled water was added to the obtained residue to dissolve it, and hydrochloric acid was added to adjust the pH to 415. The mixture was adjusted to an appropriate level and freeze-dried to obtain 14.lg of a crude product as a white solid.
- AMA dimethylaminoethyl 2-methacrylate
- This solid 7.0 g was extracted with THF using a Soxhlet extractor for 30 hours, and the solid remaining on the thimble was dissolved in water and freeze-dried to obtain 6.6 g of the target compound (A-1) as a white solid.
- the target compound (A-1) was dissolved in water and freeze-dried to obtain 6.6 g of the target compound (A-1) as a white solid.
- the repeating unit m of ethylene oxide and the repeating unit n of 2-dimethylaminoethyl methacrylate of the compound (A-1) were calculated by the formulas (1), (2) and (3).
- PEG.Mn Number average molecular weight of PEG chain obtained as a result of GPC analysis before AMA addition PAMA; Poly 2-dimethylaminoethyl methacrylate part of block copolymer PAMA.Mn; Number average of PAMA chain part of block copolymer Molecular weight
- the reaction was stopped by adding a few drops of acetic acid. Thereafter, the produced block copolymer was precipitated in cooled 2-propanol, centrifuged, the solvent was removed, and benzene was freeze-dried.
- the recovered substance was dissolved in water and adjusted to pH 4 to 5 with 1N hydrochloric acid to protonate the amino group of 2_N, N-diethylaminoethyl methacrylate.
- the protonated solution was lyophilized, and the collected product was subjected to Soxhlet extraction for one day using the solvent THF to remove unreacted prepolymer.
- Soxhlet extraction the polymer remaining on the filter was dissolved in methanol, methanol was evaporated, then dissolved in water, lyophilized, and collected.
- FIG. 3 shows the 1 H-NMR measurement results of the obtained compound in deuterated dimethyl sulfoxide.
- FIG. 4 shows the measurement results of 1 H-NMR of the obtained compound in form of double-mouthed mouth.
- Test compounds (A-1) and (A-7) were weighed at 10, 40, 80, and 160 mg, respectively,
- the aqueous solution of (NaH PO ⁇ 2 ⁇ ) was purchased from Wako Pure Chemical Industries, Ltd. and used.
- Compound (A-1) -one (A-7) was added, and each flask was mixed well. Then, it was shaken at a rotation speed of 150 rpm for 3 hours using a water bath at 25 ° C.
- test compounds (A-1) and (A-7) had a phosphate adsorption ability.
- test example 3 When 10 mg of the test compound (A-7) was weighed and stirred with 1 mL of distilled water, it became completely colorless and transparent, indicating that the product showed a solubility of 10 mg / mL or more.
- a test compound group was forcibly administered orally to 8-week-old male SD rats treated with 16 hours of fasting according to the dosages listed in Table 2, and 1 minute later, 0.5 g Zkg of phosphoric acid aqueous solution was forcibly applied. It was administered orally. Oral administration of aqueous phosphoric acid solution 15, 30, 60, 90, 120, and 180 minutes later, blood was collected from the orbital vein over time under ether anesthesia, and the collected blood was added to a tube containing a blood cell separating agent (Ceraquick-D). The serum was obtained by centrifugation at 3000 rpm Z4 ° C for 10 minutes to obtain serum.
- the concentration of phosphoric acid in the obtained serum was determined by an enzyme method (Clinical test kit: Autocella iP, Daiichi Chemical Co., Ltd.). The measurement was performed using an automatic analyzer (Hitachi Biochemical Analyzer-1 7060).
- the test was performed by simultaneously placing Sevelamer hydrochloride, an anion exchange resin (trade name: Renadiel), which is commercially available as a non-absorbable phosphorus adsorbent, as a control compound.
- an anion exchange resin trade name: Renadiel
- test compound (A-7) There was no statistically significant difference, and the 1000 mg / kg group of the test compound (A-7) also reduced serum phosphate levels, but no statistically significant difference, and the test compound (A-7) 2000 mg / kg The kg-administered group reduced serum phosphate levels and showed statistically significant differences.
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004023812 | 2004-01-30 | ||
JP2004-023812 | 2004-01-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005072752A1 true WO2005072752A1 (ja) | 2005-08-11 |
Family
ID=34823888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/001052 WO2005072752A1 (ja) | 2004-01-30 | 2005-01-27 | 高リン血症の予防又は治療剤 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2005072752A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009508580A (ja) * | 2005-09-15 | 2009-03-05 | ジェンザイム コーポレーション | アミンポリマー用サシェ製剤 |
US9579343B2 (en) | 1999-10-19 | 2017-02-28 | Genzyme Corporation | Direct compression polymer tablet core |
JP2017132746A (ja) * | 2016-01-30 | 2017-08-03 | 国立大学法人 筑波大学 | ポリイオンコンプレックスを有効成分とするドライアイ処置用組成物 |
JP2019070160A (ja) * | 2010-09-22 | 2019-05-09 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 新規ブロックコポリマーおよびミセル組成物ならびにその使用法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09295941A (ja) * | 1996-03-05 | 1997-11-18 | Mitsubishi Chem Corp | 高リン血症予防および/または治療剤 |
JPH11512074A (ja) * | 1995-06-06 | 1999-10-19 | ジェルテックス ファーマシューティカルズ,インコーポレイテッド | 経口投与用リン酸塩捕捉ポリマー |
JP2001048791A (ja) * | 1999-08-10 | 2001-02-20 | Hisamitsu Pharmaceut Co Inc | 高リン血症予防および/または治療剤 |
WO2001066606A1 (fr) * | 2000-03-09 | 2001-09-13 | Hisamitsu Pharmaceutical Co., Inc. | Resine echangeuse d'anions reticulee ou sel de celle-ci |
WO2001066607A1 (fr) * | 2000-03-09 | 2001-09-13 | Hisamitsu Pharmaceutical Co., Inc. | Resine echangeuse d'anions reticulee ou sel de celle-ci et adsorbant phosphoreux la contenant |
WO2001068106A1 (fr) * | 2000-03-13 | 2001-09-20 | Hisamitsu Pharmaceutical Co., Inc. | Prophylactiques et/ou remedes pour hyperphosphatemie |
-
2005
- 2005-01-27 WO PCT/JP2005/001052 patent/WO2005072752A1/ja active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11512074A (ja) * | 1995-06-06 | 1999-10-19 | ジェルテックス ファーマシューティカルズ,インコーポレイテッド | 経口投与用リン酸塩捕捉ポリマー |
JPH09295941A (ja) * | 1996-03-05 | 1997-11-18 | Mitsubishi Chem Corp | 高リン血症予防および/または治療剤 |
JP2001048791A (ja) * | 1999-08-10 | 2001-02-20 | Hisamitsu Pharmaceut Co Inc | 高リン血症予防および/または治療剤 |
WO2001066606A1 (fr) * | 2000-03-09 | 2001-09-13 | Hisamitsu Pharmaceutical Co., Inc. | Resine echangeuse d'anions reticulee ou sel de celle-ci |
WO2001066607A1 (fr) * | 2000-03-09 | 2001-09-13 | Hisamitsu Pharmaceutical Co., Inc. | Resine echangeuse d'anions reticulee ou sel de celle-ci et adsorbant phosphoreux la contenant |
WO2001068106A1 (fr) * | 2000-03-13 | 2001-09-20 | Hisamitsu Pharmaceutical Co., Inc. | Prophylactiques et/ou remedes pour hyperphosphatemie |
Non-Patent Citations (1)
Title |
---|
NAKAMURA T. ET AL: "Kobunshi Ronbunshu (Synthesis and cholesterol-lowering effect of poly(ethylene glycol)-polyamine graft and block polymers)", vol. 60, no. 5, 2003, pages 238 - 240, XP002997252 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9579343B2 (en) | 1999-10-19 | 2017-02-28 | Genzyme Corporation | Direct compression polymer tablet core |
US9931358B2 (en) | 1999-10-19 | 2018-04-03 | Genzyme Corporation | Direct compression polymer tablet core |
JP2009508580A (ja) * | 2005-09-15 | 2009-03-05 | ジェンザイム コーポレーション | アミンポリマー用サシェ製剤 |
US9585911B2 (en) | 2005-09-15 | 2017-03-07 | Genzyme Corporation | Sachet formulation for amine polymers |
JP2019070160A (ja) * | 2010-09-22 | 2019-05-09 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 新規ブロックコポリマーおよびミセル組成物ならびにその使用法 |
JP2017132746A (ja) * | 2016-01-30 | 2017-08-03 | 国立大学法人 筑波大学 | ポリイオンコンプレックスを有効成分とするドライアイ処置用組成物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1416942B1 (en) | Amine polymers for treating gout and binding uric acid | |
EP1392331B1 (en) | Use of colesevelam or sevelamer hydrogen chloride for lowering serum glucose | |
KR100567751B1 (ko) | 콜레스테롤과잉혈증을 치료하기 위한 폴리알릴아민 중합체 | |
KR100572785B1 (ko) | 신규한 약학 조성물 | |
US8394416B2 (en) | One step process for preparing cross-linked poly(allylamine) polymers | |
US20020187120A1 (en) | Method for treating gout and reducing serum uric acid | |
AU2002257145A1 (en) | Method for lowering serum glucose | |
EP0375350B1 (en) | Cross-linked vinylpyridinium polymers | |
US20020182168A1 (en) | Method for reducing copper levels and treating copper toxicosis | |
WO2001066606A1 (fr) | Resine echangeuse d'anions reticulee ou sel de celle-ci | |
JP2001503457A (ja) | 食物ホスフェート又はオキサレート吸収を低下させるための水溶性ポリマー | |
WO2005072752A1 (ja) | 高リン血症の予防又は治療剤 | |
JPH0330839A (ja) | ポリスチレンアニオン交換ポリマー | |
JPH07309766A (ja) | コレステロール低下剤 | |
EP1923064B1 (en) | Use of amine polymer for lowering serum glucose | |
JP2005213438A (ja) | 高コレステロール血症の予防又は治療剤 | |
WO2004011516A1 (ja) | コレステロール低下作用を有する新規化合物 | |
JP2008195701A (ja) | コレステロール低下作用を有する水溶性高分子架橋体 | |
JP2005213437A (ja) | 高コレステロール血症の予防又は治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |